Index
2008 financial crisis, 52, 60
A-7 group countries, 147
Abbott Laboratories, 47
Access to Medicines and Treatment Cam-
paign, 15, 158, 254n44
accumulation by dispossession, 255n47
active phar ma ceu ti cal ingredient(s) (api), 131,
206, 210, 262n2
actor- network theory, 254n40, 255n45
agnotology, 222
aids drugs. See antiretrovirals
All India Demo cratic Women’s Association
(aidwa), 15, 266n31
All India Drug Action Network (aidan), 158,
299n18
Amgen, 56
Andhra Pradesh, 12, 68, 71, 72, 74–75, 77–78,
81, 86, 92, 94, 172, 266n35; government, 71,
77–78, 265n22; Ministry for Health and
Family Welfare, 71, 78, 101
anticipatory knowledge, 18, 103, 132n10
antiretroviral(s), 4, 31, 61, 107, 172, 194, 196–97,
203, 249n19, 287n10, 293n53
appropriation of health by capital, 7, 22, 24–26,
32, 43, 56, 58–61, 69–70, 102, 104, 162, 220,
232, 237, 243, 245, 278n32
arbitrage, 50–51, 259n19
Arca Phar ma ceu ti cal Index, 40, 257n7
Article 21 (Indian Constitution), 150, 162, 168
assemblage(s), 255n45, 256n1; global, 255n47
Ayyangar Committee, 115, 128, 207
Azad, Ghulam Nabi, 94–98, 103, 256n33,
269n66
basic research, 139–41, 236, 298n10
Bayer, 235, 274n2, 276n10
bcr- abl, 13, 182
Belmont Report, 265n30, 271n83
Berne Declaration, 158, 284n3
beta- imatinib mesylate. See imatinib mesylate
Bharat Biotechnic, 172
Bharatiya Janata Party (bjp), 102, 145, 234,
280n45, 292n44
Bhopal, 2, 4, 35, 62, 102
Bhopal Memorial Hospital and Research
Center (bmhrc), 2
bioavailability, 58, 120–21, 124–25, 134–38,
258n12
biocapital, 252n32
bioconstitutionalism, 123, 152, 273n94
bioequivalence (studies), 64, 66–67
biological citizenship, 106
biomedical ethics, 76–77, 80, 104, 108, 238,
251n30, 263n12, 282n59
biopolitics, 59, 70, 100, 252n32, 253n38
biopharmaceutical, 39, 55, 260n22
biosociality, 106, 245
biotech(nology) com pany(ies). See
biotech(nology) industry
biotech(nology) industry, 42, 58, 261n29
blockbuster: drugs, 39–40, 44; model, 52, 54,
257n11, 261n29, 267n58
Bombay High Court, 161, 179
brand value, 196, 208, 211
Bretton Woods, 218, 293n52
bridging study, 95–98
Bristol- Myers Squibb, 235, 280n47, 285n22,
298n13
Previous Page Next Page